The city of Glendale, California, currently has 14 active clinical trials seeking participants for Healthy research studies.
A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers
Recruiting
A study to demonstrate the safety and tolerability of AZD1163 when administered intravenously and subcutaneously in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/20/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Volunteers
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
Recruiting
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess the effect of food on the safety, tolerability, and PK of orally administered AZD8965.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/13/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)
Recruiting
The goal of this study is to learn whether a new vaccine, V330, is safe and learn how well the body's immune system responds by making antibodies after receiving V330.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
02/13/2025
Locations: California Clinical Trials Medical Group managed by PAREXEL (Site 0002), Glendale, California
Conditions: Healthy
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants with Hemophilia a or Hemophilia B)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part B).
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
02/11/2025
Locations: California Clinical Trials Medical Group (CCTMG), Glendale, California
Conditions: Healthy Participants, Hemophilia A, Hemophilia B
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
Recruiting
A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity
Gender:
ALL
Ages:
Between 18 years and 142 years
Trial Updated:
02/10/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
Recruiting
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B. Part C of this study will investigate the possibility of drug-drug interaction (DDI) between IV AZD4144 and oral rosuvastatin and furosemide by evaluating the PK of rosuvastatin and furosemide when administered alone and in combination with single IV dose of AZD4144
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/10/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Recruiting
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
02/07/2025
Locations: California Clinical Trials Medical Group managed by PAREXEL ( Site 0011), Glendale, California
Conditions: Healthy
A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants
Recruiting
The purpose of this study is to examine the potential for drug-drug interactions.
Gender:
FEMALE
Ages:
Between 18 years and 35 years
Trial Updated:
01/09/2025
Locations: Early Phase Clinical Unit Los Angeles, Glendale, California
Conditions: Healthy Adult Female Participants
Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).
Recruiting
Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later. A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other t... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
12/26/2024
Locations: California Clinical Trials Medical Group managed by PAREXEL ( Site 0008), Glendale, California
Conditions: Healthy
A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants
Recruiting
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD2389 following single and multiple dose administration (SAD/MAD) to healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/20/2024
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants
Recruiting
This Phase 1, randomized, parallel-group, placebo-controlled, double-blinded study aims to evaluate the safety, PK, and PD of CKD-508 when administered multiple times once daily to healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/12/2024
Locations: Research Site, Glendale, California
Conditions: Healthy Subjects
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Non-Alcoholic Fatty Liver Disease (NAFLD)
Recruiting
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug Administration (FDA) for any kind of treatment. Part A is focused on healthy participants. Part B of the study is focused on participants who are known to have NAFLD and a specific variant of the PNPLA3 gene. The aim of the study is to see how safe, tolerable and effective the study... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/12/2024
Locations: California Clinical Trials Medical Group, Glendale, California
Conditions: Healthy Volunteers, Non-alcoholic Fatty Liver Disease (NAFLD)